Japan
# |
Name |
Net Income Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
37.24%
|
March 31, 2024 | USD 14.75 | -0.46% |
|
Japan |
|
2 |
34.34%
|
Dec. 31, 2023 | USD 9.76 | -1.43% |
|
Japan |
|
3 |
31.12%
|
Dec. 31, 2023 | USD 21.58 | 0.31% |
|
Japan |
|
4 |
29.29%
|
Dec. 31, 2023 | USD 43.39 | 5.16% |
|
Japan |
|
5 |
25.91%
|
March 31, 2024 | USD 15.25 | -1.27% |
|
Japan |
|
6 |
25.46%
|
March 31, 2024 | USD 10.39 | -0.80% |
|
Japan |
|
7 |
22.05%
|
Aug. 31, 2024 | USD 9.32 | -2.24% |
|
Japan |
|
8 |
20.91%
|
March 31, 2024 | USD 10.95 | -0.53% |
|
Japan |
|
9 |
20.47%
|
Oct. 31, 2023 | USD 5.47 | -1.74% |
|
Japan |
|
10 |
20.40%
|
Dec. 31, 2023 | USD 5.86 | -2.20% |
|
Japan |
|
11 |
19.01%
|
Sept. 30, 2024 | USD 12.23 | -2.54% |
|
Japan |
|
12 |
18.95%
|
March 31, 2024 | USD 9.15 | -1.97% |
|
Japan |
|
13 |
18.37%
|
Sept. 30, 2024 | USD 2.93 | -1.24% |
|
Japan |
|
14 |
18.36%
|
Dec. 31, 2023 | USD 14.95 | -1.71% |
|
Japan |
|
15 |
17.44%
|
March 31, 2024 | USD 24.26 | -0.77% |
|
Japan |
|
16 |
17.19%
|
Aug. 31, 2024 | USD 13.43 | 0.52% |
|
Japan |
|
17 |
15.25%
|
Dec. 31, 2023 | USD 3.39 | -1.15% |
|
Japan |
|
18 |
14.77%
|
March 31, 2024 | USD 25.51 | -0.96% |
|
Japan |
|
19 |
14.76%
|
Dec. 31, 2023 | USD 3.77 | -0.24% |
|
Japan |
|
20 |
14.70%
|
June 30, 2024 | USD 16.87 | -2.21% |
|
Japan |
|
21 |
14.63%
|
March 31, 2024 | USD 9.19 | -0.31% |
|
Japan |
|
22 |
14.23%
|
March 31, 2024 | USD 25.58 | -1.99% |
|
Japan |
|
23 |
13.87%
|
Oct. 31, 2024 | USD 76.41 | -0.92% |
|
Japan |
|
24 |
13.66%
|
Dec. 31, 2023 | USD 9.78 | -1.94% |
|
Japan |
|
25 |
13.39%
|
March 31, 2024 | USD 10.75 | -2.71% |
|
Japan |
|
26 |
13.32%
|
March 31, 2024 | USD 43.36 | -1.17% |
|
Japan |
|
27 |
13.32%
|
Sept. 30, 2024 | USD 9.46 | -2.05% |
|
Japan |
|
28 |
13.11%
|
March 31, 2024 | USD 11.36 | -0.42% |
|
Japan |
|
29 |
12.85%
|
March 31, 2024 | USD 3.56 | -3.55% |
|
Japan |
|
30 |
12.53%
|
March 31, 2024 | USD 27.56 | -3.63% |
|
Japan |
|
31 |
11.54%
|
March 31, 2024 | USD 18.88 | -4.20% |
|
Japan |
|
32 |
11.44%
|
March 31, 2024 | USD 4.97 | -1.23% |
|
Japan |
|
33 |
11.14%
|
March 31, 2024 | USD 29.12 | 0.44% |
|
Japan |
|
34 |
11.14%
|
March 31, 2024 | USD 27.19 | -2.00% |
|
Japan |
|
35 |
11.08%
|
March 31, 2024 | USD 29.51 | -0.48% |
|
Japan |
|
36 |
10.76%
|
March 31, 2024 | USD 19.21 | -1.38% |
|
Japan |
|
37 |
10.57%
|
Dec. 31, 2023 | USD 13.83 | -0.63% |
|
Japan |
|
38 |
10.42%
|
March 31, 2024 | USD 13.76 | -1.19% |
|
Japan |
|
39 |
10.21%
|
March 31, 2024 | USD 14.41 | -0.72% |
|
Japan |
|
40 |
9.91%
|
Sept. 30, 2024 | USD 3.00 | -0.80% |
|
Japan |
|
41 |
9.86%
|
Feb. 29, 2024 | USD 28.70 | -1.67% |
|
Japan |
|
42 |
8.94%
|
June 30, 2024 | USD 8.27 | -1.43% |
|
Japan |
|
43 |
8.85%
|
March 31, 2024 | USD 8.69 | -1.39% |
|
Japan |
|
44 |
8.55%
|
March 31, 2024 | USD 12.31 | 0.15% |
|
Japan |
|
45 |
7.98%
|
March 31, 2024 | USD 17.95 | -0.66% |
|
Japan |
|
46 |
7.74%
|
March 31, 2024 | USD 12.96 | -0.41% |
|
Japan |
|
47 |
7.67%
|
March 31, 2024 | USD 14.30 | -1.12% |
|
Japan |
|
48 |
7.57%
|
March 31, 2024 | USD 17.48 | -1.21% |
|
Japan |
|
49 |
7.22%
|
March 31, 2024 | USD 3.38 | -1.89% |
|
Japan |
|
50 |
7.20%
|
March 31, 2024 | USD 11.15 | -1.27% |
|
Japan |
The Healthcare company in Japan with the highest Net Income Margin is Shionogi & Co., Ltd. (Tokyo Stock Exchange: 4507.T) at 37.24%.
The Healthcare company in Japan with the lowest Net Income Margin is BrightPath Biotherapeutics Co., Ltd. (Tokyo Stock Exchange: 4594.T) at -1,622,336.11%.
The top 10 Healthcare companies in Japan by Net Income Margin are Shionogi & Co., Ltd., Mizuho Medy Co.,Ltd., GNI Group Ltd., Chugai Pharmaceutical Co., Ltd., Olympus Corporation, Ono Pharmaceutical Co., Ltd., Mani, Inc., Shin Nippon Biomedical Laboratories, Ltd., CellSource Co., Ltd. and FINDEX Inc..
The bottom 10 Healthcare companies in Japan by Net Income Margin are BrightPath Biotherapeutics Co., Ltd., Oncolys BioPharma Inc., NanoCarrier Co., Ltd., OncoTherapy Science, Inc., Solasia Pharma K.K., MEDINET Co., Ltd., Welby Inc., Carna Biosciences, Inc., Nxera Pharma Co., Ltd. and SymBio Pharmaceuticals Limited.